ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2021
Strategies for Implementation Research to Investigate the Negative Pharmacokinetic Interaction Between Efavirenz and Dolutegravir.
Gene D Morse
Open access · greenAbstract readEditorialComment
In one paragraphArticle in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 94% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed, 0 citations in OpenAlex.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
1 author at 1 institution in 1 country.
Gene D MorseUniversity at Buffalo, Buffalo, New York, USA.
University at Buffalo, State University of New York · US
Funding
Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1MStatistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6MValidation, CLIA and Qualification (VQC): Enhancing the RS ratio as a tool for AIDS Clinical Trial Group (ACTG) tuberculosis trialsUM1AI106701 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Grace M Aldrovandi · 2014 to 2026
$116.8MUniversity of Buffalo Clinical and Translational Science Institute - Supplement SchulyerUL1TR001412 · NCATS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI MURPHY, TIMOTHY F · 2015 to 2024
$33.8MHIV Research Training ProgramD43TW010313 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Charles Enos Chiedza Maponga, Gene D. Morse · 2016 to 2026
$3.2MGlobal Infectious Diseases Research Training ProgramD43TW010919 · FIC · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI Kathryn B Anderson, John Fitzgerald Lindo · 2018 to 2026
$2.5MFIC NIH HHS D43 TW010313FIC NIH HHS D43 TW010919NCATS NIH HHS UL1 TR001412NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636NIAID NIH HHS UM1 AI106701
6 · The paper itselfAbstract
PubMed holds no abstract for this paper.
Indexed as
BenzoxazinesHeterocyclic Compounds, 3-RingAlkynesCyclopropanesDolutegravirHumansOxazinesPiperazinesPyridonesAlkynesBenzoxazinesCyclopropanesDolutegravirefavirenzHeterocyclic Compounds, 3-RingOxazinesPiperazinesPyridonesdolutegravirdrug interactionefavirenzimplementation research
Identifiers
PMID32667998
PMCPMC8130025
OpenAlexW3043161048
What OpenQuestion holds
Textmetadata
Read underepoch 390